Skip to main
PEN

Penumbra (PEN) Stock Forecast & Price Target

Penumbra (PEN) Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 20%
Buy 13%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Penumbra is being acquired by Boston Scientific in a stock-and-cash transaction that values the company's enterprise value at $14.5B. This acquisition is a strategic move for Boston Scientific, as it gains access to Penumbra's differentiated technology platform and its strong market position in the high-growth VTE market. Additionally, we expect to see continued growth and innovation in Penumbra's neurovascular franchise, which will likely drive further adoption and market share. However, potential changes in reimbursement could have a negative impact on Penumbra's business. Overall, we believe Boston Scientific is paying a fair price for Penumbra and do not anticipate any other bidders to emerge.

Bears say

Penumbra is facing competition in the neurovascular market from larger and more established companies like Medtronic, Stryker, Boston Scientific, Johnson & Johnson, and Terumo. The recent acquisition by Boston Scientific at a high valuation highlights the company's market potential and growth opportunities in the peripheral vascular space. However, risks to our neutral rating include macroeconomic headwinds and potential for future competition and slippage in product timelines.

Penumbra (PEN) has been analyzed by 15 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 13% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Penumbra (PEN) Forecast

Analysts have given Penumbra (PEN) a Hold based on their latest research and market trends.

According to 15 analysts, Penumbra (PEN) has a Hold consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $362, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $362, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Penumbra (PEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.